METABOLIK SINDROMDA HAYZ SIKLI BUZILISHLARINING PATOGENETIK MEXANIZMLARI
Keywords:
metabolik sindrom, hayz sikli buzilishlari, insulin rezistentligi, giperandrogenizm, ko‘p kistali tuxumdon sindromi, anovulyatsiya, gipotalamus–gipofiz–tuxumdon o‘qi.Abstract
Metabolik sindrom – insulin rezistentligi, abdominal semirish, arterial gipertoniya va dislipidemiya bilan kechuvchi murakkab simptomatik kompleks bo‘lib, so‘nggi yillarda uning tarqalishi sezilarli darajada oshib bormoqda. Ushbu patologiya ayollarning reproduktiv salomatligiga bevosita ta’sir ko‘rsatib, hayz sikli buzilishlarining rivojlanishiga olib keladi.
Tadqiqot maqsadi – metabolik sindrom sharoitida hayz sikli buzilishlarining asosiy patogenetik mexanizmlarini ilmiy adabiyotlar asosida tizimli ravishda tahlil qilish hisoblanadi.
References
1. Азизова Ф.Л., Каримова Н.А. Метаболический синдром и репродуктивное здоровье женщин. Проблемы биологии и медицины. 2022;(4):15–21.
2. Ayubxanov Sh.E., Asadova N.K. Metabolik sindromning ayollar reproduktiv tizimiga ta'siri. Tibbiyotda yangi kun. 2023;2(52):78–83.
3. Манухин И.Б., Тумилович Л.Г., Геворкян М.А. Гинекологическая эндокринология. Клинические лекции. 4-е изд. Москва: ГЭОТАР-Медиа; 2020. 304 с.
4. Dunaif A, Fauser BCJM. Renaming PCOS – a two-state solution. J Clin Endocrinol Metab. 2013;98(11):4325–4328. https://doi.org/10.1210/jc.2013-2040
5. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284. https://doi.org/10.1038/nrendo.2018.24
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41–47. https://doi.org/10.1093/humrep/deh098
7. Hall JE. Neuroendocrine control of the menstrual cycle. In: Strauss JF, Barbieri RL, editors. Yen & Jaffe's Reproductive Endocrinology. 8th ed. Philadelphia: Elsevier; 2019. p. 149–166.
8. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042. https://doi.org/10.1177/1179558119874042
9. Zuo T, Zhu M, Xu J. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev. 2016;2016:8589318. https://doi.org/10.1155/2016/8589318
10. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. https://doi.org/10.1093/humrep/dey256
11. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003
12. Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. Reprod Biomed Online. 2006;12(5):542–551. https://doi.org/10.1016/S1472-6483(10)61179-0
References (transliteration)
1. Azizova FL, Karimova NA. Metabolicheskiy sindrom i reproduktivnoe zdorovye zhenshchin [Metabolic syndrome and women's reproductive health]. Problemy biologii i meditsiny. 2022;(4):15–21. (In Russ.)
2. Ayubxanov ShE, Asadova NK. Metabolik sindromning ayollar reproduktiv tizimiga ta'siri [The impact of metabolic syndrome on women's reproductive system]. Tibbiyotda yangi kun. 2023;2(52):78–83. (In Uzb.)
3. Manukhin IB, Tumilovich LG, Gevorkyan MA. Ginekologicheskaya endokrinologiya. Klinicheskie lektsii [Gynecological endocrinology. Clinical lectures]. 4th ed. Moscow: GEOTAR-Media; 2020. 304 p. (In Russ.)
